Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer

Digestive and Liver Disease

Volumn 46, Issue 9, 2014, Pages 846-853

  Yoo, Eun Jin ^a   Park, Jun Chul ^a   Kim, Eun Hye ^a   Park, Chan Hyuk ^a   Shim, Choong Nam ^a   Lee, Hyun Jik ^a   Chung, Hyun Soo ^a   Lee, Hyuk ^a   Shin, Sung Kwan ^a   Lee, Sang Kil ^a   Lee, Chang Geol ^a   Lee, Yong Chan ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Concurrent chemoradiotherapy; Neutrophil to lymphocyte ratio; Oesophageal cancer; Prognosis

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN;

ADVANCED CANCER; AGED; ARTICLE; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; ESOPHAGUS CANCER; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPHIL LYMPHOCYTE RATIO; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE DISTRIBUTION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; ESOPHAGEAL NEOPLASMS; KAPLAN MEIER METHOD; LYMPHOCYTE; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; SOUTH KOREA; AREA UNDER THE CURVE; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; LEUKOCYTE COUNT; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; ORAL MUCOSITIS; PLATELET LYMPHOCYTE RATIO; RADIATION INJURY; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTOPENIA; WEAKNESS;

AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; MALE; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84906306748     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.05.009     Document Type: Article

References (34)

1. Thomas P., Doddoli C., Lienne P., et al. Changing patterns and surgical results in adenocarcinoma of the oesophagus. British Journal of Surgery 1997, 84:119-125.
2. Herskovic A., Martz K., al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. New England Journal of Medicine 1992, 326:1593-1598.
3. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced oesophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. Journal of the American Medical Association 1999, 281:1623-1627.
4. Wong R., Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database of Systematic Reviews 2001, CD002092.
5. Shim H.J., Kim D.E., Hwang J.E., et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemotherapy and Pharmacology 2012, 70:683-690.
6. Iwase H., Shimada M., Tsuzuki T., et al. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced oesophageal cancer: long-term results of a phase II trial. Oncology 2013, 84:342-349.
7. Semrau R., Herzog S.L., Vallbohmer D., et al. Prognostic factors in definitive radiochemotherapy of advanced inoperable oesophageal cancer. Diseases of the Esophagus 2012, 25:545-554.
8. Bromwich E., McMillan D.C., Lamb G.W., et al. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. British Journal of Cancer 2004, 91:1236-1238.
9. Andreyev H.J., Norman A.R., Oates J., et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies. European Journal of Cancer 1998, 34:503-509.
10. Dutta S., Crumley A.B., Fullarton G.M., et al. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World Journal of Surgery 2011, 35:1861-1866.
11. McMillan D.C. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treatment Reviews 2013, 39:534-540.
12. Roxburgh C.S., McMillan D.C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncology 2010, 6:149-163.
13. Proctor M.J., McMillan D.C., Morrison D.S., et al. A derived neutrophil-to-lymphocyte ratio predicts survival in patients with cancer. British Journal of Cancer 2012, 107:695-699.
14. Balta S., Demirkol S., Unlu M., et al. Neutrophil-to-lymphocyte ratio may be predict of mortality in all conditions. British Journal of Cancer 2013, 109:3125-3126.
15. Guthrie G.J., Charles K.A., Roxburgh C.S., et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Critical Reviews in Oncology/Hematology 2013, 88:218-230.
16. Noble F., Hopkins J., Curtis N., et al. The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Medical Oncology 2013, 30:596.
17. Sharaiha R.Z., Halazun K.J., Mirza F., et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in oesophageal cancer. Annals of Surgical Oncology 2011, 18:3362-3369.
18. Sato H., Tsubosa Y., Kawano T. Correlation between the pretherapeutic neutrophil-to-lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced oesophageal cancer. World Journal of Surgery 2012, 36:617-622.
19. Sanjay P., de Figueiredo R.S., Leaver H., et al. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Journal of the Pancreas 2012, 13:199-204.
20. Quint L.E., Bogot N.R. Staging oesophageal cancer. Cancer Imaging 2008, 8(Spec. No. A):S33-S42.
21. Schneeweiss S., Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. International Journal of Epidemiology 2000, 29:891-898.
22. Proctor M.J., Morrison D.S., Talwar D., et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. British Journal of Cancer 2011, 104:726-734.
23. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology 2003, 13:176-181.
24. van Persijn van Meerten E.L., Gelderblom H., Bloem J.L. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. European Radiology 2010, 20:1456-1467.
25. Fujita H., Tsubuku T., Tanaka T., et al. Guidelines for the diagnosis and treatment of oesophageal cancer: clinical efficacy and impact. Nippon Geka Gakkai Zasshi 2007, 108:246-252.
26. Yin J., Tian L. Joint confidence region estimation for area under ROC curve and Youden index. Statistics in Medicine 2014, 33:985-1000.
27. Proctor M.J., Morrison D.S., Talwar D., et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. European Journal of Cancer 2011, 47:2633-2641.
28. Bhutta H., Agha R., Wong J., et al. Neutrophil-lymphocyte ratio predicts medium-term survival following elective major vascular surgery: a cross-sectional study. Vascular and Endovascular Surgery 2011, 45:227-231.
29. Fock R.A., Blatt S.L., Beutler B., et al. Study of lymphocyte subpopulations in bone marrow in a model of protein-energy malnutrition. Nutrition 2010, 26:1021-1028.
30. Fridlender Z.G., Sun J., Kim S., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell 2009, 16:183-194.
31. Kobayashi T., Teruya M., Kishiki T., et al. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with oesophageal squamous cell carcinoma. Surgery 2008, 144:729-735.
32. Ohno Y., Nakashima J., Ohori M., et al. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. Journal of Urology 2012, 187:411-417.
33. Di Fiore A., Lecleire S., Gangloff A., et al. Impact of nutritional parameter variations during definitive chemoradiotherapy in locally advanced oesophageal cancer. Digestive and Liver Disease 2014, 46:270-275.
34. Kim D.E., Kim U.J., Choi W.Y., et al. Clinical prognostic factors for locally advanced oesophageal squamous carcinoma treated after definitive chemoradiotherapy. Cancer Research and Treatment 2013, 45:276-284.